Consultant-Needed-Insert
X

Find Clinical Drug Pipeline Developments & Deals for Lidocaine

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lidocaine,Hyaluronic Acid

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Crescita Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Distribution Agreement January 20, 2020

            Details:

            The partnership with FILLMED will allow Crescita to expand its product offering in the medical aesthetic field with the addition of the hyaluronic acid ART-Filler® injectables range and NCTF® 135 HA.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hyaluronic Acid,Lidocaine

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Revance Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 09, 2020

            Details:

            Under the agreement Revance will gain immediate and exclusive rights to commercialize TEOXANE’s RHA® line of fillers in the U.S.